Paper Details
- Home
- Paper Details
Topical calcineurin inhibitors as a double-edged sword in rosacea: A systematic review.
Author: FangRouyu, SunQiuning, TangKeyun, WangYuchen, YangLeyan, ZhangDingyue, ZhangHanlin
Original Abstract of the Article :
BACKGROUND: Rosacea is a chronic inflammatory disease mainly with skin or ocular manifestations. Topical calcineurin inhibitors, pimecrolimus and tacrolimus, can be used to treat rosacea. However, they can also induce rosacea-like eruptions. AIMS: This study systematically reviewed the double-edged...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1111/jocd.14315
データ提供:米国国立医学図書館(NLM)
Topical Calcineurin Inhibitors: A Double-Edged Sword in Rosacea
This systematic review investigates the complex effects of [topical calcineurin inhibitors] on [rosacea], a chronic inflammatory skin condition. The researchers reviewed the available literature on the use of pimecrolimus and tacrolimus, two topical calcineurin inhibitors, for treating rosacea, exploring their potential benefits and risks.
Potential Benefits and Risks of Topical Calcineurin Inhibitors
The review highlights the double-edged sword nature of topical calcineurin inhibitors in rosacea. While these agents can be effective in treating some forms of rosacea, they can also induce rosacea-like eruptions in susceptible individuals. This complex relationship emphasizes the need for careful patient selection and monitoring when considering topical calcineurin inhibitors for treating rosacea.
The Need for Further Research
The review concludes that further research is needed to clarify the specific roles of pimecrolimus and tacrolimus in treating and inducing rosacea. Larger, well-designed clinical trials are required to provide more definitive evidence regarding their efficacy and safety profile in treating rosacea. Additionally, further research into the mechanisms underlying their effects on rosacea could lead to improved understanding and more targeted treatment approaches.
Dr.Camel's Conclusion
This systematic review offers a valuable overview of the complex relationship between topical calcineurin inhibitors and rosacea. The researchers' findings highlight the need for caution and careful consideration when using these agents to treat rosacea. It's a reminder that even seemingly promising treatments can have unexpected consequences, emphasizing the importance of ongoing research to optimize therapeutic approaches and minimize adverse effects.
Date :
- Date Completed 2022-04-05
- Date Revised 2022-04-05
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.